Prestizia Oncology Panels
Solid Tumors
Key Facts
About Theradiag
Theradiag's mission is to advance personalized medicine through specialized diagnostic solutions for monitoring complex chronic diseases. The company has achieved a strong position in the European market for therapeutic drug monitoring of autoimmune diseases with its flagship Lisa-Tracker platform. Its strategy focuses on expanding its molecular diagnostics portfolio, forging strategic partnerships for commercial reach, and capitalizing on the growing demand for companion diagnostics in biotherapy management. As a publicly traded entity, Theradiag balances R&D investment with commercial execution to drive growth.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |